A number of other research analysts have also weighed in on HCP. Mizuho set a $26.00 price target on shares of HCP and gave the company a buy rating in a research note on Thursday. Jefferies Group reaffirmed a hold rating and issued a $26.00 price target on shares of HCP in a research note on Tuesday, February 13th. BMO Capital Markets set a $25.00 price target on shares of HCP and gave the company a hold rating in a research note on Tuesday, February 13th. Stifel Nicolaus reaffirmed a buy rating and issued a $27.00 price target (down previously from $29.00) on shares of HCP in a research note on Wednesday. Finally, ValuEngine lowered shares of HCP from a buy rating to a hold rating in a research note on Friday, February 2nd. Four analysts have rated the stock with a sell rating, ten have assigned a hold rating and four have issued a buy rating to the company’s stock. The company currently has a consensus rating of Hold and an average price target of $28.62.
HCP (HCP) opened at $22.68 on Thursday. The company has a quick ratio of 0.61, a current ratio of 0.31 and a debt-to-equity ratio of 1.23. HCP has a one year low of $21.64 and a one year high of $33.67. The firm has a market cap of $10,463.90, a P/E ratio of 26.37, a price-to-earnings-growth ratio of 4.07 and a beta of 0.27.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 2nd. Stockholders of record on Thursday, February 15th will be issued a $0.37 dividend. The ex-dividend date of this dividend is Wednesday, February 14th. This represents a $1.48 dividend on an annualized basis and a dividend yield of 6.53%. HCP’s dividend payout ratio (DPR) is presently 172.09%.
In other HCP news, insider Kendall K. Young acquired 14,000 shares of the stock in a transaction dated Wednesday, February 14th. The shares were bought at an average cost of $21.91 per share, for a total transaction of $306,740.00. Following the completion of the acquisition, the insider now directly owns 48,544 shares of the company’s stock, valued at $1,063,599.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 0.22% of the stock is owned by company insiders.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Vestpro Financial Partners Inc. dba CPF Texas acquired a new position in HCP during the fourth quarter worth $103,000. Advisory Services Network LLC increased its holdings in HCP by 4.1% during the second quarter. Advisory Services Network LLC now owns 3,782 shares of the real estate investment trust’s stock worth $121,000 after buying an additional 150 shares during the last quarter. Fieldpoint Private Securities LLC acquired a new position in HCP during the third quarter worth $147,000. Penserra Capital Management LLC acquired a new position in HCP during the third quarter worth $163,000. Finally, Koch Industries Inc. acquired a new position in HCP during the second quarter worth $208,000. Institutional investors own 90.23% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This piece was first posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of US & international copyright laws. The correct version of this piece can be read at https://www.chaffeybreeze.com/2018/02/18/robert-w-baird-reiterates-24-00-price-target-for-hcp-hcp.html.
HCP, Inc is a self-administered real estate investment trust. The Company invests in real estate serving the healthcare industry in the United States. The Company’s segments include senior housing triple-net (SH NNN), senior housing operating portfolio (SHOP), life science and medical office. Its senior housing facilities include independent living facilities, assisted living facilities, memory care facilities, care homes, and continuing care retirement communities.
Receive News & Ratings for HCP Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCP and related companies with MarketBeat.com's FREE daily email newsletter.